Page last updated: 2024-09-04

purpurin 18 and ER-Negative PR-Negative HER2-Negative Breast Cancer

purpurin 18 has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Huang, P; Leung, W; Xu, C; Yuan, Q; Zhang, B; Zhang, X	1

Other Studies

1 other study(ies) available for purpurin 18 and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Photodynamic treatment with purpurin 18 effectively inhibits triple negative breast cancer by inducing cell apoptosis. Lasers in medical science, 2021, Volume: 36, Issue:2 Topics: Animals; Apoptosis; Body Weight; Cell Line, Tumor; Female; Humans; Light; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Mitochondria; Optical Imaging; Photochemotherapy; Photosensitizing Agents; Porphyrins; Spheroids, Cellular; Subcellular Fractions; Triple Negative Breast Neoplasms; Tumor Burden	2021

Article

Year

Photodynamic treatment with purpurin 18 effectively inhibits triple negative breast cancer by inducing cell apoptosis.

Lasers in medical science, 2021, Volume: 36, Issue:2

Topics: Animals; Apoptosis; Body Weight; Cell Line, Tumor; Female; Humans; Light; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Mitochondria; Optical Imaging; Photochemotherapy; Photosensitizing Agents; Porphyrins; Spheroids, Cellular; Subcellular Fractions; Triple Negative Breast Neoplasms; Tumor Burden

2021